Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical 5-fluorouracil for actinic keratosis in renal transplant recipients
ACTRN12609000622202Phase 4Not yet recruiting
- Sponsor
- Dr Warren Weightman
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluorouracil in actinic keratosis (AK), sponsored by Dr Warren Weightman. Primary endpoints: Complete clearance rate in actinic keratosis surface area at 12 months and Complete clearance rate in actinic keratosis surface area at 8 weeks. Planned start Sep 2009; status: not yet recruiting.
02
Drugs
fluorouracil
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on ACTRN12609000622202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000622202.